AJOG:低剂量阿司匹林是否可降低高风险孕妇的子痫前期风险?

2021-08-17 Nebula MedSci原创

低剂量阿司匹林已经成为最研究广泛的子痫前期预防药物,它真的能降低高风险妊娠女性的子痫前期风险吗?

低剂量阿司匹林已经成为最研究广泛的子痫前期预防药物。但是,各国关于阿司匹林在子痫前期的预防性应用指南存在相当大的差异。目前大型试验的证据有限,无法明确100 mg 阿司匹林对高危孕妇子痫前期筛查的影响,也无法指导低剂量阿司匹林在中国子痫前期预防中的应用。

低剂量阿司匹林在中国子痫前期预防(APPEC)研究旨在评估100 mg 阿司匹林在根据孕妇风险因素筛查的高风险妊娠女性中预防子痫前期的效果

这是一项于2016年-2019年期间在中国11个省的13家医院开展的多中心随机对照试验,研究人员假设,子痫前期的发生率相对降低至少20%,即对照组和阿司匹林组的发生率分别是20%和16%。招募受试者目标数量1000人,1:1随机分至两组。主要终点是子痫前期的发生率,即既往血压正常,孕20周后收缩压(SBP)≥140 mmHg或舒张压(DBP)≥90 mmHg。次要终点包括孕妇和新生儿的预后。

两组间的主要和次要终点

2016年12月-2019年3月,招募了1000位符合要求的女性,最后其中898位被纳入意向治疗分析(阿司匹林组 464位、对照组 434位)。阿司匹林组和对照组间的子痫前期发生率没有明显的差异(16.8% vs 17.1%;RR 0.986 [95%CI 0.738-1.317];p=0.924)。同样的,两组间孕产妇和新生儿的不良结局发生率也没有显著差异。此外,阿司匹林组和对照组的产后大出血发生率也相似(6.5% vs 5.3%;RR 1.220 [95%CI 0.720-2.066];p=0.459)。

不同孕前BMI女性亚组的两组子痫前期发生率

最后,在不同风险因素的亚组分析中,两组间的子痫前期发生率也没有表现出任何明显差异。

综上,在中国,从孕12-20周开始每天服用100 mg 阿司匹林直到孕34周,并不能降低高风险因素的妊娠女性子痫前期的发生率

原始出处:

Lin Li,Huai Jing,Li Boya et al. A randomized controlled trial of low-dose aspirin for the prevention of pre-eclampsia in women at high-risk in China (the APPEC study).[J] .Am J Obstet Gynecol, 2021, https://www.ajog.org/article/S0002-9378(21)00869-3/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862170, encodeId=013b18621e0aa, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 07 14:06:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007480, encodeId=1f95200e480e6, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Wed Nov 17 22:06:18 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197918, encodeId=019f119e91846, content=这个结论需要再次验证吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd175543794, createdName=zlzl, createdTime=Mon Feb 28 07:51:09 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366581, encodeId=cadd136658144, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480604, encodeId=cfd8148060443, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009206, encodeId=b7be100920614, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Wed Aug 18 18:31:15 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009103, encodeId=309910091033d, content=这惊了 临床一直这么用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12a25573232, createdName=ms4000000314404532, createdTime=Wed Aug 18 15:09:33 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008904, encodeId=12a6100890473, content=阿司匹林用处多~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Aug 18 07:34:38 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862170, encodeId=013b18621e0aa, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 07 14:06:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007480, encodeId=1f95200e480e6, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Wed Nov 17 22:06:18 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197918, encodeId=019f119e91846, content=这个结论需要再次验证吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd175543794, createdName=zlzl, createdTime=Mon Feb 28 07:51:09 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366581, encodeId=cadd136658144, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480604, encodeId=cfd8148060443, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009206, encodeId=b7be100920614, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Wed Aug 18 18:31:15 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009103, encodeId=309910091033d, content=这惊了 临床一直这么用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12a25573232, createdName=ms4000000314404532, createdTime=Wed Aug 18 15:09:33 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008904, encodeId=12a6100890473, content=阿司匹林用处多~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Aug 18 07:34:38 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862170, encodeId=013b18621e0aa, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 07 14:06:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007480, encodeId=1f95200e480e6, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Wed Nov 17 22:06:18 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197918, encodeId=019f119e91846, content=这个结论需要再次验证吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd175543794, createdName=zlzl, createdTime=Mon Feb 28 07:51:09 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366581, encodeId=cadd136658144, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480604, encodeId=cfd8148060443, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009206, encodeId=b7be100920614, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Wed Aug 18 18:31:15 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009103, encodeId=309910091033d, content=这惊了 临床一直这么用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12a25573232, createdName=ms4000000314404532, createdTime=Wed Aug 18 15:09:33 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008904, encodeId=12a6100890473, content=阿司匹林用处多~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Aug 18 07:34:38 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2022-02-28 zlzl

    这个结论需要再次验证吧!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1862170, encodeId=013b18621e0aa, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 07 14:06:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007480, encodeId=1f95200e480e6, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Wed Nov 17 22:06:18 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197918, encodeId=019f119e91846, content=这个结论需要再次验证吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd175543794, createdName=zlzl, createdTime=Mon Feb 28 07:51:09 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366581, encodeId=cadd136658144, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480604, encodeId=cfd8148060443, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009206, encodeId=b7be100920614, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Wed Aug 18 18:31:15 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009103, encodeId=309910091033d, content=这惊了 临床一直这么用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12a25573232, createdName=ms4000000314404532, createdTime=Wed Aug 18 15:09:33 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008904, encodeId=12a6100890473, content=阿司匹林用处多~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Aug 18 07:34:38 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-19 yahu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1862170, encodeId=013b18621e0aa, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 07 14:06:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007480, encodeId=1f95200e480e6, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Wed Nov 17 22:06:18 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197918, encodeId=019f119e91846, content=这个结论需要再次验证吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd175543794, createdName=zlzl, createdTime=Mon Feb 28 07:51:09 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366581, encodeId=cadd136658144, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480604, encodeId=cfd8148060443, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009206, encodeId=b7be100920614, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Wed Aug 18 18:31:15 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009103, encodeId=309910091033d, content=这惊了 临床一直这么用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12a25573232, createdName=ms4000000314404532, createdTime=Wed Aug 18 15:09:33 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008904, encodeId=12a6100890473, content=阿司匹林用处多~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Aug 18 07:34:38 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1862170, encodeId=013b18621e0aa, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 07 14:06:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007480, encodeId=1f95200e480e6, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Wed Nov 17 22:06:18 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197918, encodeId=019f119e91846, content=这个结论需要再次验证吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd175543794, createdName=zlzl, createdTime=Mon Feb 28 07:51:09 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366581, encodeId=cadd136658144, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480604, encodeId=cfd8148060443, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009206, encodeId=b7be100920614, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Wed Aug 18 18:31:15 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009103, encodeId=309910091033d, content=这惊了 临床一直这么用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12a25573232, createdName=ms4000000314404532, createdTime=Wed Aug 18 15:09:33 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008904, encodeId=12a6100890473, content=阿司匹林用处多~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Aug 18 07:34:38 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-18 春江水暖

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1862170, encodeId=013b18621e0aa, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 07 14:06:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007480, encodeId=1f95200e480e6, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Wed Nov 17 22:06:18 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197918, encodeId=019f119e91846, content=这个结论需要再次验证吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd175543794, createdName=zlzl, createdTime=Mon Feb 28 07:51:09 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366581, encodeId=cadd136658144, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480604, encodeId=cfd8148060443, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009206, encodeId=b7be100920614, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Wed Aug 18 18:31:15 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009103, encodeId=309910091033d, content=这惊了 临床一直这么用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12a25573232, createdName=ms4000000314404532, createdTime=Wed Aug 18 15:09:33 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008904, encodeId=12a6100890473, content=阿司匹林用处多~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Aug 18 07:34:38 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-18 ms4000000314404532

    这惊了 临床一直这么用的

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1862170, encodeId=013b18621e0aa, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 07 14:06:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007480, encodeId=1f95200e480e6, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Wed Nov 17 22:06:18 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197918, encodeId=019f119e91846, content=这个结论需要再次验证吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd175543794, createdName=zlzl, createdTime=Mon Feb 28 07:51:09 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366581, encodeId=cadd136658144, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480604, encodeId=cfd8148060443, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Aug 19 14:06:18 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009206, encodeId=b7be100920614, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Wed Aug 18 18:31:15 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009103, encodeId=309910091033d, content=这惊了 临床一直这么用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12a25573232, createdName=ms4000000314404532, createdTime=Wed Aug 18 15:09:33 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008904, encodeId=12a6100890473, content=阿司匹林用处多~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Aug 18 07:34:38 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-18 学医无涯

    阿司匹林用处多~

    0

相关资讯

Liver Int:阿司匹林和他汀类药物与慢性乙肝患者的肝癌风险的相关性

他汀类药物与HCC风险降低呈剂量依赖性相关性

Heart:阿司匹林与P2Y12抑制剂联合抗凝治疗对房颤的疗效分析

在长期服用利伐沙班和P2Y12抑制剂或阿司匹林的AF和稳定性CAD患者的心血管和出血事件没有显著差异。

J Periodontol:牙周清创后辅助使用ω-3和ASA有益于治疗2型糖尿病患者的牙周炎

补充ω-3多不饱和脂肪酸(ω-3 PUFA)和低剂量阿司匹林(ASA)已被提议作为控制慢性炎症性疾病的宿主调节方案。本研究旨在调查口服ω-3 PUFA和ASA作为牙

JGH: 阿司匹林相关溃疡出血患者使用质子泵抑制剂联合阿司匹林或氯吡格雷的不良事件风险分析

有基础冠状动脉和脑血管疾病的患者往往需要终生使用阿司匹林,但是这有可能会导致消化性溃疡病 (PUD) 以及消化道出血的发生。一般可以通过同时使用质子泵抑制剂

Br J Cancer:阿司匹林增强顺铂治疗食管鳞癌的疗效

食管癌(EC)作为中国第三大常见的癌症和第四大癌症死亡原因,据估计,每年有477,900例新发病例和375,000例死亡病例。

阿司匹林与消化道肿瘤——降低60%发病风险,提高一倍生存率!

阿司匹林诞生一百多年来,最先用于解热镇痛药,后来科学家对其研究发现越来越多的用途,小到解热镇痛,预防血栓,大到防治疗肿瘤。它是当之无愧的“神药”。本文简单介绍它在肿瘤防治方面的最新研究成果。